- Home
- CJET vs CING Comparison
CJET vs CING Comparison
Compare CJET & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- CING
- Stock Information
- Founded
- CJET 2009
- CING 2012
- Country
- CJET China
- CING United States
- Employees
- CJET N/A
- CING N/A
- Industry
- CJET Auto Manufacturing
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- CJET Consumer Discretionary
- CING Health Care
- Exchange
- CJET Nasdaq
- CING Nasdaq
- Market Cap
- CJET 14.3M
- CING 15.3M
- IPO Year
- CJET N/A
- CING 2021
- Fundamental
- Price
- CJET $1.76
- CING $4.76
- Analyst Decision
- CJET
- CING Strong Buy
- Analyst Count
- CJET 0
- CING 2
- Target Price
- CJET N/A
- CING $12.00
- AVG Volume (30 Days)
- CJET 69.5K
- CING 216.3K
- Earning Date
- CJET 01-28-2025
- CING 11-07-2024
- Dividend Yield
- CJET N/A
- CING N/A
- EPS Growth
- CJET N/A
- CING N/A
- EPS
- CJET N/A
- CING N/A
- Revenue
- CJET $10,275,000.00
- CING N/A
- Revenue This Year
- CJET N/A
- CING N/A
- Revenue Next Year
- CJET N/A
- CING N/A
- P/E Ratio
- CJET N/A
- CING N/A
- Revenue Growth
- CJET 31.31
- CING N/A
- 52 Week Low
- CJET $1.65
- CING $1.80
- 52 Week High
- CJET $23.94
- CING $62.70
- Technical
- Relative Strength Index (RSI)
- CJET 37.95
- CING 52.86
- Support Level
- CJET $1.93
- CING $4.27
- Resistance Level
- CJET $2.08
- CING $5.16
- Average True Range (ATR)
- CJET 0.17
- CING 0.42
- MACD
- CJET -0.06
- CING -0.01
- Stochastic Oscillator
- CJET 10.71
- CING 37.18
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.